Northrop Grumman's shares were essentially unchanged, rising a modest 0.3% following Q2 earnings that featured solid bookings and backlog growth but were weighed down by margin pressure from two key programs and elevated costs in missile qualification testing.
Northrop Grumman delivered a strong start to 2026 with 5% organic sales growth driven by increased modernizations and a robust defense budget environment, supported by solid bookings and expanding production capacity.
Northrop Grumman reported solid Q3 2025 results with mid-single-digit revenue growth, a significant increase in free cash flow, and improved operating margins, despite a downward revision of full-year revenue guidance.